We used Kaplan–Meier plotter to analyze 177 PAAD samples and found that for overall survival (OS), YOD1 hazard ratio (HR) = 2.14 (1.29–3.56, P = 0.0025) and for relapse-free survival (RFS), YOD1 HR = 3.37 (1.32–8.6, P = 0.0068) (Fig. 4A, B). Therefore, the high expression of YOD1 is significantly positively correlated with the poor prognosis of PAAD patients. We also obtained the same results in GEPIA database. Here, YOD1 is linked to pancreatic adenocarcinoma.